Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says

Regeneron Pharmaceuticals (REGN) is expected to grapple with Q1 seasonality when reporting March quarter results early next month, despite the ongoing Eylea HD launch, Oppenheimer said in a note Thurs

MT NewswiresApr 27 00:24

Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125

Regeneron Pharmaceuticals (REGN) has an average rating of outperform and price targets ranging from $720 to $1,189, according to analysts polled by Capital IQ. Price: 885.00, Change: -5.68, Percent Ch

MT NewswiresApr 26 20:24

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study

Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study of upadacitinib (Rinvoq, 15 mg once daily starting dos

BenzingaApr 26 01:58

Global Pulmonary Drugs Market Is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Grifols, Regeneron

Yahoo FinanceApr 26 01:00

Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma -- WSJ

By David Wainer Bristol-Myers Squibbs market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnin

WSJApr 25 23:15

Regeneron (REGN) Reports Next Week: What You Should Expect

Yahoo FinanceApr 25 22:02